Monday, June 22
FDA reversal sends gene therapy stock soaring
A surprise regulatory about-face on a fatal brain disease treatment was the sharpest single move in the market today, but it shared the stage with a brutal Oracle layoff count and a messy day for Meta.
Top Stories
The FDA's reversal vindicates a company most investors had written off
Regenxbio surged after the FDA dropped a demand that had previously blocked its application for Navsunli, a treatment for a rare and deadly brain disease in children, clearing the path to an accelerated approval filing that the agency had once seemed to slam shut.
This is what a regulatory second chance looks like in biotech: the FDA's original objection, requiring some children in the study to go without treatment, was both scientifically contested and ethically fraught, and the agency's willingness to reverse course suggests the underlying data was strong enough to force a rethink.
Oracle's 21,000-person workforce cut is a warning about what AI adoption actually costs humans
Oracle quietly shed roughly 13% of its global workforce over the past fiscal year, one of the largest tech layoffs in recent memory, with AI-driven restructuring cited as a central reason for eliminating tens of thousands of jobs.
The company offered no public guidance or explanation alongside the numbers, which is itself a signal: when a company stays silent about cuts this large, it usually means the restructuring is ongoing and the final shape is not yet clear.
Merck's drug pipeline is quietly becoming one of the most reliable in medicine
Merck reported that its bowel disease drug hit its main trial target while a fresh FDA approval for its flagship cancer treatment in an earlier stage of kidney disease added another win to an already strong stretch.
While Pfizer stumbled today on a lung cancer drug that failed its own late-stage trial, Merck's pattern of clinical successes is making it look like the steadier hand in a sector where most bets do not pay off.
Also Today
- Lucid's second mass layoff this year signals survival risk
- Companywide leak exposed employee keystrokes, halting Meta's AI training
- UPS expands into temperature-controlled healthcare logistics across 27 locations
Takeaway
Today split cleanly between companies proving their bets are paying off, like Merck and Regenxbio, and companies whose restructuring stories are getting harder to spin as progress, like Oracle and Lucid.
The most concrete thing to watch next is whether Regenxbio moves quickly to refile its application now that the FDA has cleared the path, since the speed of that refiling will signal how ready the data actually is.
